BRPI0406643A - Uso de moduladores do receptor alfa de estrogênio para o tratamento de esclerose multipla - Google Patents

Uso de moduladores do receptor alfa de estrogênio para o tratamento de esclerose multipla

Info

Publication number
BRPI0406643A
BRPI0406643A BR0406643-0A BRPI0406643A BRPI0406643A BR PI0406643 A BRPI0406643 A BR PI0406643A BR PI0406643 A BRPI0406643 A BR PI0406643A BR PI0406643 A BRPI0406643 A BR PI0406643A
Authority
BR
Brazil
Prior art keywords
estrogen receptor
treatment
multiple sclerosis
receptor modulators
alpha
Prior art date
Application number
BR0406643-0A
Other languages
English (en)
Inventor
M Merle Elloso
Robert Mitchell
Douglas C Harnish
Steven J Adelman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0406643A publication Critical patent/BRPI0406643A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"USO DE MODULADORES DO RECEPTOR ALFA DE ESTROGêNIO PARA O TRATAMENTO DE ESCLEROSE MULTIPLA". A presente invenção proporciona métodos de tratamento de patologia autoimune em um mamífero compreendendo administração de um agente com atividade agonista do receptor de estrogênio, em particular um modulador seletivo do receptor de estrogênio, a um mamífero um uma quantidade suficiente para diminuir a produção de citocinas TH-1 e/ou TH-2. Também proporcionado é um método de seleção de compostos úteis para o tratamento de esclerose múltipla compreendendo seleção de um composto o qual tem atividade agonista do receptor de estrogênio.
BR0406643-0A 2003-01-06 2004-01-05 Uso de moduladores do receptor alfa de estrogênio para o tratamento de esclerose multipla BRPI0406643A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43812303P 2003-01-06 2003-01-06
PCT/US2004/000037 WO2004062653A2 (en) 2003-01-06 2004-01-05 The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis

Publications (1)

Publication Number Publication Date
BRPI0406643A true BRPI0406643A (pt) 2005-12-06

Family

ID=32713279

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406643-0A BRPI0406643A (pt) 2003-01-06 2004-01-05 Uso de moduladores do receptor alfa de estrogênio para o tratamento de esclerose multipla

Country Status (14)

Country Link
US (1) US20040167112A1 (pt)
EP (1) EP1585507A2 (pt)
JP (1) JP2006515616A (pt)
KR (1) KR20050091058A (pt)
CN (1) CN1723013A (pt)
AU (1) AU2004204675A1 (pt)
BR (1) BRPI0406643A (pt)
CA (1) CA2512021A1 (pt)
EC (1) ECSP055950A (pt)
MX (1) MXPA05007317A (pt)
NO (1) NO20053156L (pt)
RU (1) RU2005125043A (pt)
WO (1) WO2004062653A2 (pt)
ZA (1) ZA200505400B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042172A2 (en) * 2004-10-09 2006-04-20 The Regents Of The University Of Michigan Gender differences in experimental aortic aneurysm formation
WO2011014516A1 (en) 2009-07-28 2011-02-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Estrogen antagonists as treatments for sclerosing disorders
EP3189853A4 (en) * 2014-08-04 2018-07-11 Nitto Denko Corporation Immune-induction-promoting composition including nuclear receptor ligand, and vaccine pharmaceutical composition
KR20190042028A (ko) * 2016-08-12 2019-04-23 더 리전트 오브 더 유니버시티 오브 캘리포니아 재수초화 요법
KR102817163B1 (ko) * 2022-08-04 2025-06-05 고려대학교 산학협력단 바제독시펜을 유효성분으로 포함하는 염증성 피부질환의 예방 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5521198A (en) * 1993-12-21 1996-05-28 Eli Lilly And Company Methods of inhibiting autoimmune diseases
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5434166A (en) * 1994-08-22 1995-07-18 Eli Lilly And Company Methods of inhibiting demyelinating and desmyelinating diseases
JPH10513470A (ja) * 1995-02-06 1998-12-22 イーライ・リリー・アンド・カンパニー Ｉｌ−６の効果を阻害する方法
US6545027B1 (en) * 1995-06-07 2003-04-08 Eli Lilly And Company Methods of modulating NF-kB transcription factor
US6353003B1 (en) * 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
AU5984701A (en) * 2000-05-12 2001-11-20 Univ Oregon Health & Science Method of treating immune pathologies with low dose estrogen
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases

Also Published As

Publication number Publication date
ECSP055950A (es) 2006-01-16
EP1585507A2 (en) 2005-10-19
RU2005125043A (ru) 2006-01-27
JP2006515616A (ja) 2006-06-01
CA2512021A1 (en) 2004-07-29
MXPA05007317A (es) 2005-09-30
AU2004204675A1 (en) 2004-07-29
KR20050091058A (ko) 2005-09-14
NO20053156L (no) 2005-09-08
US20040167112A1 (en) 2004-08-26
CN1723013A (zh) 2006-01-18
WO2004062653A3 (en) 2004-11-04
WO2004062653A2 (en) 2004-07-29
ZA200505400B (en) 2006-12-27
NO20053156D0 (no) 2005-06-28

Similar Documents

Publication Publication Date Title
ES2575152T3 (es) Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
BR0114758A (pt) Inibidores do receptor ep4 para tratamento de artrite reumatóide
EP1651161A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR ACCELERATING WOUND HEALING
AR046290A1 (es) Agente terapeutico para el mesotelioma
CO5670359A2 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes
EA021242B9 (ru) Антитела к остеопротегерин лиганду (опгл)
BR0315597A (pt) Processos de baixa dose para tratamento de distúrbios em que a atividade de tnf(alfa)é prejudicial
ATE552790T1 (de) Knochenfixationssystem
BRPI0415397A (pt) métodos e reagentes para o tratamento de desordens imunoinflamatórias
BR0317110A (pt) Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
NO20043013L (no) Tetrahydrokinolin analoger som muskarine agonister
BR0212877A (pt) Emulsão de água-em-óleo, composição, e, métodos para umectar pele de mamìfero, para desinfetar tecido de mamìfero e para suprir um agente farmacêutico a um mamìfero
BRPI0414277A (pt) métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
BR0016665A (pt) Composição alvejante, e, métodos de alvejamento e de preparação de uma composição alvejante
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
MX2009013699A (es) Aplicador de una composicion para el tratamiento del cabello.
FI960727A0 (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
BRPI0520465A2 (pt) implante poroso
CR9849A (es) Agonistas del receptor gamma activado por el proliferador de peroxisomas para la mejora de la funcion cognitiva en pacientes con apolipoproteina e4 negativa
DE60122337D1 (de) Verwendung von taci als antitumormittel
BR9813677A (pt) Composição para cuidado oral, e, uso de um ácido poliacrìlico totalmente neutralizado
BRPI0412971A (pt) método de alongamento do cabelo
BRPI0406643A (pt) Uso de moduladores do receptor alfa de estrogênio para o tratamento de esclerose multipla
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired